48,706
edits
(prognosticator) |
|||
(3 intermediate revisions by 2 users not shown) | |||
Line 22: | Line 22: | ||
| Symptoms = | | Symptoms = | ||
| Prevalence = common for site | | Prevalence = common for site | ||
| Bloodwork = | | Bloodwork = elevated CA19-9 | ||
| Rads = pancreatic mass | | Rads = pancreatic mass | ||
| Endoscopy = | | Endoscopy = | ||
Line 55: | Line 55: | ||
#TP53 (AKA p53). | #TP53 (AKA p53). | ||
#SMAD4. | #SMAD4. | ||
Clinical: | |||
*Serum CA19-9 - >2504 U/ml predicts outcome.<ref name=pmid28924968>{{Cite journal | last1 = Usón Junior | first1 = PLS. | last2 = Callegaro-Filho | first2 = D. | last3 = Bugano | first3 = DDG. | last4 = Moura | first4 = F. | last5 = Maluf | first5 = FC. | title = Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. | journal = J Gastrointest Cancer | volume = 49 | issue = 4 | pages = 481-486 | month = Dec | year = 2018 | doi = 10.1007/s12029-017-0007-x | PMID = 28924968 }}</ref> | |||
==Gross== | ==Gross== | ||
Features:<ref name="pmid2015921">{{ | Features:<ref name="pmid2015921">{{Cite journal | last1 = Hermanek | first1 = P. | title = Staging of exocrine pancreatic carcinoma. | journal = Eur J Surg Oncol | volume = 17 | issue = 2 | pages = 167-72 | month = Apr | year = 1991 | doi = | PMID = 2015921 }}</ref> | ||
*Firm, sclerotic and poorly defined masses that replace the normal lobular architecture of the gland. | *Firm, sclerotic and poorly defined masses that replace the normal lobular architecture of the gland. | ||
*Cut surface are yellow to white. | *Cut surface are yellow to white. |
edits